These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2521269)

  • 1. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial.
    MacMahon S; Collins G; Rautaharju P; Cutler J; Neaton J; Prineas R; Crow R; Stamler J
    Am J Cardiol; 1989 Jan; 63(3):202-10. PubMed ID: 2521269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
    Bang CN; Soliman EZ; Simpson LM; Davis BR; Devereux RB; Okin PM;
    Am J Hypertens; 2017 Sep; 30(9):914-922. PubMed ID: 28430947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group.
    Am J Cardiol; 1985 Jan; 55(1):1-15. PubMed ID: 3880997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN; Devereux RB; Okin PM
    J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy.
    Liebson PR
    Am J Hypertens; 1990 Jun; 3(6 Pt 1):512-7. PubMed ID: 2142430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
    Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM; Hille DA; Kjeldsen SE; Devereux RB
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
    Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
    J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension Detection and Follow-up Program Cooperative Group.
    Hypertension; 1985; 7(1):105-12. PubMed ID: 3156812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
    Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
    Gerdts E; Okin PM; Boman K; Wachtell K; Nieminen MS; Dahlöf B; Devereux RB
    Am J Hypertens; 2012 Jun; 25(6):678-83. PubMed ID: 22456225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial.
    Ernst ME; Neaton JD; Grimm RH; Collins G; Thomas W; Soliman EZ; Prineas RJ;
    Hypertension; 2011 Dec; 58(6):1001-7. PubMed ID: 22025372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
    Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.